612 related articles for article (PubMed ID: 30066039)
21. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
Magenau J; Westervelt P; Khaled S; McGuirk J; Hari P; Eapen M; Becker PS; Parkin B; Braun T; Logan B; Wang H; Jagasia M; Rowley SD; Kim DD; Schechter T; Frey N; Scott B; Churay T; Lieland S; Forman S; Mineishi S
Bone Marrow Transplant; 2017 Jan; 52(1):59-65. PubMed ID: 27427921
[TBL] [Abstract][Full Text] [Related]
22. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
23. The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
Wang Z; Yin C; Zhang W; Tang W; Song X; Hu X; Ni X; Qiu H; Yang J; Hu J; Wang J
Ann Hematol; 2019 Jul; 98(7):1765-1773. PubMed ID: 30993416
[TBL] [Abstract][Full Text] [Related]
24. T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.
How J; Slade M; Vu K; DiPersio JF; Westervelt P; Uy GL; Abboud CN; Vij R; Schroeder MA; Fehniger TA; Romee R
Biol Blood Marrow Transplant; 2017 Apr; 23(4):648-653. PubMed ID: 28087457
[TBL] [Abstract][Full Text] [Related]
25. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
[TBL] [Abstract][Full Text] [Related]
26. Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Gu B; Wu X; Chen G; Ma X; Jin Z; Tang X; Han Y; Fu C; Qiu H; Sun A; Wu D
Leuk Res; 2017 Aug; 59():41-46. PubMed ID: 28549237
[TBL] [Abstract][Full Text] [Related]
27. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
29. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.
Eapen M; Rubinstein P; Zhang MJ; Camitta BM; Stevens C; Cairo MS; Davies SM; Doyle JJ; Kurtzberg J; Pulsipher MA; Ortega JJ; Scaradavou A; Horowitz MM; Wagner JE
J Clin Oncol; 2006 Jan; 24(1):145-51. PubMed ID: 16382124
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia.
Yalniz FF; Saliba RM; Greenbaum U; Ramdial J; Popat U; Oran B; Alousi A; Olson A; Alatrash G; Marin D; Rezvani K; Hosing C; Im J; Mehta R; Qazilbash M; Joseph JJ; Rondon G; Kanagal-Shamanna R; Shpall E; Champlin R; Kebriaei P
Transplant Cell Ther; 2021 Aug; 27(8):689-695. PubMed ID: 34023569
[TBL] [Abstract][Full Text] [Related]
31. Nationwide survey of therapy-related leukemia in childhood in Japan.
Imamura T; Taga T; Takagi M; Kawasaki H; Koh K; Taki T; Adachi S; Manabe A; Ishida Y; ;
Int J Hematol; 2018 Jul; 108(1):91-97. PubMed ID: 29574603
[TBL] [Abstract][Full Text] [Related]
32. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
Kumar AJ; Vassilev P; Loren AW; Luger SM; Reshef R; Gill S; Smith J; Goldstein SC; Hexner E; Stadtmauer EA; Porter D; Frey NV
Am J Hematol; 2016 Jun; 91(4):426-9. PubMed ID: 26820493
[TBL] [Abstract][Full Text] [Related]
33. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Bone Marrow Transplant; 2015 Nov; 50(11):1405-10. PubMed ID: 26168067
[TBL] [Abstract][Full Text] [Related]
34. Unrelated hematopoietic stem cell transplantation for children with acute leukemia: experience at a single institution.
Lee JH; Yoon HS; Song JS; Choi ES; Moon HN; Seo JJ; Im HJ
J Korean Med Sci; 2009 Oct; 24(5):904-9. PubMed ID: 19794991
[TBL] [Abstract][Full Text] [Related]
35. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
Kharfan-Dabaja MA; Labopin M; Brissot E; Kroger N; Finke J; Ciceri F; Deconinck E; Blaise D; Chevallier P; Gramatzki M; Ganser A; Stelljes M; Edinger M; Savani B; Ruggeri A; Sanz J; Nagler A; Mohty M
Br J Haematol; 2021 May; 193(3):592-601. PubMed ID: 33838047
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis.
Shimizu H; Saitoh T; Machida S; Kako S; Doki N; Mori T; Sakura T; Kanda Y; Kanamori H; Miyawaki S; Okamoto S;
Eur J Haematol; 2015 Nov; 95(5):455-60. PubMed ID: 25605541
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
38. Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia.
Lee JH; Lee JH; Kim DY; Yun SC; Kim SD; Choi Y; Lee YS; Kang YA; Jeon MJ; Seol M; Lee KH
Eur J Haematol; 2011 Aug; 87(2):172-81. PubMed ID: 21599753
[TBL] [Abstract][Full Text] [Related]
39. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.
Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Solh M; Bashey A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1816-1822. PubMed ID: 27453362
[TBL] [Abstract][Full Text] [Related]
40. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
